NATCO Pharma obtains a favorable ruling on Copaxone

29 Jul 2013 Evaluate

US Court of Appeals for the Federal Circuit has given a ruling in NATCO Pharma’s favour by allowing it to launch a copycat version of Copaxone through its marketing partner Mylan Inc during May 2014. Copaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis. The product is estimated to have clocked revenues, in USA, of about $ 3.45 billion during 2012.

Earlier this month, the company received marketing approval for its Rizatriptan Benzoate (Maxalt-MLD) orally disintegrating tablets, 5 mg and 10 mg (base) from US Food & Drug Administration (USFDA).

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

918.75 51.25 (5.91%)
11-Dec-2025 13:51 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.45
Dr. Reddys Lab 1275.50
Cipla 1511.40
Zydus Lifesciences 925.70
Lupin 2082.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×